Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jeffrey B. Locke"'
Autor:
Dávid Balázsi, Zoltán Tóth, Jeffrey B. Locke, Andrew M. Borman, Lajos Forgács, Noémi Balla, Fruzsina Kovács, Renátó Kovács, Chiaki Amano, Tugba Ilay Baran, László Majoros
Publikováno v:
Journal of Fungi, Vol 10, Iss 9, p 617 (2024)
Objectives: Rezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different Cand
Externí odkaz:
https://doaj.org/article/ca17088ce19e49fc9a9f6f8d23363b35
Autor:
Renátó Kovács, Zoltán Tóth, Jeffrey B. Locke, Lajos Forgács, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, László Majoros
Publikováno v:
Microorganisms, Vol 9, Iss 4, p 863 (2021)
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolate
Externí odkaz:
https://doaj.org/article/3ff1c0616e624441b8f476fa2d8ca064
Autor:
Zoltán Tóth, Lajos Forgács, Tamás Kardos, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, Awid Adnan, László Majoros
Publikováno v:
Journal of Fungi, Vol 6, Iss 3, p 136 (2020)
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and an
Externí odkaz:
https://doaj.org/article/a23d6cbe580347f09bb0724220ec9922
Publikováno v:
Infectious Diseases in Obstetrics and Gynecology, Vol 2018 (2018)
Background. While echinocandins demonstrate excellent efficacy against Candida species in disseminated infections and demonstrate potent minimal inhibitory concentration (MIC) values under standard susceptibility testing conditions, investigation und
Externí odkaz:
https://doaj.org/article/e7de552cd67d427c9398709ded9333f5
Autor:
Douglas E Zuill, Amanda L Almaguer, Joanna Donatelli, Maiken Cavling Arendrup, Jeffrey B Locke
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:1102-1110
Background Rezafungin is a novel, once-weekly echinocandin. EUCAST rezafungin MIC testing has been associated with a good separation of WT and target gene mutant isolates in single-centre studies, but an unacceptable inter-laboratory MIC variation ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d9bb05e9359f4004d08e750e2522355
https://doi.org/10.1093/jac/dkad055
https://doi.org/10.1093/jac/dkad055
Autor:
George R Thompson, Alex Soriano, Oliver A Cornely, Bart-Jan Kullberg, Marin Kollef, Jose A Vazquez, Anita F Das, Jeffrey B Locke, Taylor Sandison, Peter G Pappas
Publikováno v:
Open Forum Infectious Diseases. 9
Background Rezafungin is a next-generation, once-weekly echinocandin in development for treatment of candidemia and invasive candidiasis (IC), and for prevention of invasive fungal diseases caused by Candida, Aspergillus, and Pneumocystis in allogene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c0851827f02e7eefbbe0fd7be57cb77
https://doi.org/10.1093/ofid/ofac492.309
https://doi.org/10.1093/ofid/ofac492.309
Publikováno v:
Open Forum Infectious Diseases. 9
Background Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which have higher predisposition to develop antifungal resistance (e.g., fks mutations conferring reduced susceptibility to echinocandins)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26ea862b210f436fd207863ebf479d72
https://doi.org/10.1093/ofid/ofac492.644
https://doi.org/10.1093/ofid/ofac492.644
Autor:
Maiken Cavling Arendrup, Sevtap Arikan-Akdagli, Mariana Castanheira, Jesus Guinea, Jeffrey B Locke, Joseph Meletiadis, Oscar Zaragoza
Publikováno v:
The Journal of antimicrobial chemotherapy, 78(1), 185-195. Oxford University Press
Objectives Rezafungin EUCAST MIC testing has been associated with notable inter-laboratory variation, which prevented ECOFF setting for C. albicans. We assessed in vitro susceptibility and reproducibility for a modified EUCAST methodology and establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f76de4ee437ee1852acac9ac93ad22aa
https://pubmed.ncbi.nlm.nih.gov/36329639
https://pubmed.ncbi.nlm.nih.gov/36329639
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Autor:
Lajos Forgács, Zoltán Tóth, Fruzsina Nagy, Andrew M. Borman, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Adrien Szekely, László Majoros
Publikováno v:
Journal of Antimicrobial Chemotherapy
BackgroundRezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.MethodsWe determined the in vitro susceptibility of 689 clinical isolates of 5 com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cd874efd8f120c01ecbc1cbe1c2b7e
http://europepmc.org/articles/PMC6857195
http://europepmc.org/articles/PMC6857195
Autor:
László Majoros, Gábor Kardos, Lajos Forgács, Renátó Kovács, Andrew M. Borman, Zoltán Tóth, Jeffrey B. Locke, Fruzsina Nagy
Publikováno v:
Microorganisms, Vol 9, Iss 863, p 863 (2021)
Microorganisms
Volume 9
Issue 4
Microorganisms
Volume 9
Issue 4
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85db3469351f7f843869f70307b55f6b
https://www.mdpi.com/2076-2607/9/4/863
https://www.mdpi.com/2076-2607/9/4/863